Hypereosinophilic syndromes

HES Hypereosinophilic syndrome HETE 5,8,9,11,12 and 15 Hydroxyeicosatetraenoic acid 5(S)HETE A stereo isomer of 5-HETE... 

IGSS Immuno-gold silver stain IHC Immunohistochemistry IHES Idiopathic hypereosinophilic syndrome... 

Unlabeled Uses Dermographism, eczema, hypereosinophilic syndrome, hypopig-mented sarcoidosis, ichthyosis linearis circumflexa, lymphomatoid papulosis, mycosis fungoides, palmoplantar pustulosis, pruritus, scleromyxedema, systemic sclero-... 

Cardiovascular effects. Hypotension and tachycardia occur in most patients taking clozapine. Cases of potentially fatal myocarditis and dilated cardiomyopathy have been reported in association with clozapine (Kilian et al. 1999). Myocarditis typically occurred within 3 weeks of starting clozapine, but cardiomyopathy may not be apparent for several years. Although rare, treatment-emergent myocarditis and cardiomyopathy occur at a reportedly higher incidence with clozapine than with other antipsychotics (Coulter et al. 2001). The mechanism by which clozapine may cause myocarditis has not been established, but some authors have speculated that clozapine may cause an immunoglobuhn E (IgE)-mediated type 1 hypersensitivity reaction (Kihan et al. 1999) or a hypereosinophilic syndrome (Hagg et al. 2001). 

Malbrain ML, Van den Bergh H, Zachee E Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome complete haematological and cytogenetic remission induced by interferon-a in a case with a unique chromosomal abnormality. Br J Haematol 1996 92 176-83. 

Messie K, Vovor A, Kueviakoe IM, Sallah LK, Agbetiafa K, Segbena AY. Qonal hypereosinophilic syndrome two cases report in black men from sub-Saharan A ica and literature reviews. BRN Hematol. 2011 2011 974609. doi 10.5402/2011/974609. 

Table 6 Distinctive Characteristics of the Lymphocytic and the Myeloproliferative Variants of the Hypereosinophilic Syndromes...

Chusid MJ, Dale DC, West BC, et al. The hypereosinophilic syndrome analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975 54 1-27. 

Roufosse F, Goldman M, Cogan E. Hypereosinophilic syndrome lymphoproli-ferative and myeloprohferative variants. Semin Respir Crit Care Med 2006 27 158-170. 

Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med 2003 54 169-184. 

CiUoni D, Messa E, MartineUi G, et al. WTl transcript amount discriminates secondary or reactive eosinophiha from idiopathic hypereosinophilic syndrome or chronic eosinophihc leukemia. Leukemia 2007 21 1442-1450. 

Fauci AS, Harley JB, Roberts WC, et al. The idiopathic hypereosinophilic syndrome clinical, pathophysiologic and therapeutic considerations. Ann Intern Med 1982 97 78-92. 

Cools J, DeAngelo DJ, GotUb J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIPILI genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2(X)3 348 1201-1214. 

Griffin JH, Leung J, Bruner RJ, et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A 2003 1(X) 7830 835. 

KUon AD, Law MA, Noel P, et al. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004 103 2939-2941. 

Surface FceRI expression on peripheral blood eosinophils has been variably observed in vivo since the first report of the high-affinity receptor on blood eosinophils (90) and remains a topic of controversy (91). The initial description involved blood eosinophils from subjects with hypereosinophilic syndromes (90), but subsequent studies have failed to reproduce these observations (85,92). Blood eosinophils express both mRNA and intracellular protein for the a and y subunits of the FceRI receptor complex but lack the P subunit protein. Eosinophils in culture with IL-5 release the a subunit protein into the culture supernatant, but the addition of IgE failed to induce expression of the receptor on the cell surface... 

---